‘King Kong’ drug Mounjaro now in short supply into 2024

Recently launched diabetes med with weight loss hype another victim of ‘larger than expected demand’ Mounjaro, the hotly anticipated competitor to social media-hyped diabetes and de facto weight loss drug Ozempic, has itself become the victim of unexpected demand, seemingly primarily from the off-label weight-loss market. Quietly launched barely two months ago in comparatively inconvenient

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous ‘Stark look’ at work that still needs doing on vaccination
Next Over and under: counting antivenom stocks